Berkeley Lights Inc represents a commitment to innovation, collaboration, and ethical practices in the biotechnology industry. With a strong corporate philosophy centered on driving advancements in cell biology, their cutting-edge technology platform empowers researchers to accelerate the discovery and development of new therapies. Berkeley Lights Inc values continuous learning and a customer-centric approach, enabling scientists to gain valuable insights and make informed decisions. The company's dedication to unlocking the full potential of cell-based research is reflected in their ongoing efforts to revolutionize the way scientists study and treat diseases. Through their integrated solutions, Berkeley Lights Inc strives to improve the efficiency and effectiveness of biopharmaceutical development.

Berkeley Lights Inc is primarily present in the United States.

Berkeley Lights Inc has achieved several significant milestones. The company successfully launched its flagship platform, the Beacon Optofluidic System, which revolutionizes biopharmaceutical discovery and development processes. Additionally, Berkeley Lights Inc introduced the Opto Cell Therapy Development System, facilitating the discovery and characterization of cell-based therapies. The company's innovative technology has garnered recognition and numerous accolades, including being named one of the World's Most Innovative Companies by Fast Company in 2020. Furthermore, Berkeley Lights Inc has established collaborations with leading pharmaceutical companies to advance research and drug development. These milestones highlight the company's commitment to advancing scientific discovery and driving progress in the biotechnology field.

Berkeley Lights Inc, founded in 2011, is a leading digital cell biology company that enables the acceleration of discoveries and development of biological products. Headquartered in Emeryville, California, the company has revolutionized the way biological research is conducted with its proprietary technology, the Beacon platform. This platform combines biology, automation, and technology to deliver customizable solutions for analyzing, characterizing, and manipulating individual cells in a high-throughput manner. Berkeley Lights Inc has emerged as a trusted partner for pharmaceutical, biotech, and academic institutions, providing them with powerful tools to advance various fields, including cell line development, antibody discovery, and functional genomics. With an innovative approach and a strong commitment to scientific excellence, the company continues to drive breakthroughs in the life sciences industry.

The main competitors of Berkeley Lights Inc in the market are companies like Illumina Inc, Fluidigm Corporation, and NanoString Technologies Inc.

Berkeley Lights Inc is primarily active in the biotechnology industry.

The business model of Berkeley Lights Inc is a leading provider of cell biology platforms and technologies for biotechnology and pharmaceutical companies. Their proprietary platforms enable the discovery and development of innovative therapies by combining biotechnology, automation, and artificial intelligence. With their platforms, researchers can accelerate the identification, characterization, and manipulation of cells for various applications, such as drug discovery, antibody development, and cell therapy. Berkeley Lights Inc's focus on pioneering technologies and solutions has positioned them as a trusted partner in the biotech industry, driving advancements in cell-based research and ultimately improving patient outcomes.

P/E odnos PhenomeX iznosi -1,16.

KUV kompanije PhenomeX iznosi 0,66.

AlleAktien kvalitativni skor za PhenomeX je 3/10.

očekivana PhenomeX promet je 104,06 mil. USD.

Dobit očekivana PhenomeX je -59,16 mil. USD.

Berkeley Lights Inc specializes in developing cell-based solutions for the biotech and pharmaceutical sectors. They offer a unique platform technology called Beacon, which allows for the identification, selection, and isolation of individual cells. The company's business model is based on three pillars: the Beacon platform, associated services, and consumer goods. The Beacon platform is the core of the business model, allowing for the manipulation of cells at a rate of up to 10,000 per second. Associated services involve applying the Beacon platform to various fields, such as analyzing customers' own cells to enhance understanding of their functions, identifying, characterizing, and isolating active substances, and offering services for the development of biological therapeutics and vaccines. The third pillar involves offering consumer goods necessary for using the Beacon platform, including microchips, reagents, and media. Berkeley Lights Inc serves various industries, including biotech and pharmaceutical companies, academic institutions, and government agencies. The platform technology finds applications in many areas, such as cell expression, gene editing, cell-line development, immunotherapy, and antibody research. Despite being a relatively young company, Berkeley Lights Inc has quickly become an important partner in innovative medical research. It has proven its ability to bring groundbreaking technology to the market, supporting biotech and pharmaceutical research in multiple ways. The Beacon platform offers engineers, researchers, and scientists a fast and effective method for cell characterization and isolation, enabling the development of better therapies and vaccines. Listed on the Nasdaq stock exchange, Berkeley Lights Inc has experienced strong growth, with investors recognizing the value of its innovative technology and forward-thinking business model. Through its Beacon technology, the company contributes significantly to biotech and pharmaceutical research by developing new drugs and therapies capable of treating a wide range of diseases. In summary, the Beacon platform is a unique and versatile tool for optimizing cell analysis and therapeutic development. With a well-balanced strategy of platform development, services, and consumer goods, Berkeley Lights Inc offers a wide range of solutions for various industries. Furthermore, the company actively contributes to the exploration of therapeutics that can help patients with different diseases.

PhenomeX isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za PhenomeX trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od PhenomeX je US0843101017.

WKN od PhenomeX je A2P9RR.

Oznaka za praćenje akcija kompanije PhenomeX je CELL.

U poslednjih 12 meseci, PhenomeX je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, PhenomeX će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od PhenomeX trenutno iznosi .

PhenomeX isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

PhenomeX je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

PhenomeX se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od PhenomeX od 1. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 1. 10. 2024..

Isplata poslednje dividende izvršena je 1. 10. 2024..

U godini 2023 kompanija PhenomeX je isplatila 0 USD kao dividende.

Dividende od PhenomeX se isplaćuju u USD.